Advertisement
Advertisement
U.S. markets closed
Advertisement
Advertisement
Advertisement
Advertisement

Virax Biolabs Group Limited (VRAX)

NasdaqCM - NasdaqCM Real Time Price. Currency in USD
1.5650+0.2450 (+18.56%)
At close: 03:59PM EST
1.5800 +0.01 (+0.96%)
After hours: 07:59PM EST
Advertisement
Full screen
Trade prices are not sourced from all markets
Gain actionable insight from technical analysis on financial instruments, to help optimize your trading strategies
Chart Events
Neutralpattern detected
Commodity Channel Index

Commodity Channel Index

Previous Close1.3200
Open1.3200
Bid1.5000 x 800
Ask1.5800 x 1000
Day's Range1.2600 - 1.6200
52 Week Range1.2400 - 29.0000
Volume335,941
Avg. Volume2,375,057
Market Cap20.076M
Beta (5Y Monthly)N/A
PE Ratio (TTM)N/A
EPS (TTM)N/A
Earnings DateN/A
Forward Dividend & YieldN/A (N/A)
Ex-Dividend DateN/A
1y Target EstN/A
Fair Value is the appropriate price for the shares of a company, based on its earnings and growth rate also interpreted as when P/E Ratio = Growth Rate. Estimated return represents the projected annual return you might expect after purchasing shares in the company and holding them over the default time horizon of 5 years, based on the EPS growth rate that we have projected.
Fair Value
XX.XX
Overvalued

Subscribe to Yahoo Finance Plus to view Fair Value for VRAX

View details
Research that delivers an independent perspective, consistent methodology and actionable insight
Related Research
  • Virax Biolabs Group Limited
    Daily – Vickers Top Insider Picks for 11/30/2022The Vickers Top Insider Picks is a daily report that utilizes a proprietary algorithm to identify 25 companies with compelling insider purchase histories based on transactions over the past three months.
    Rating
    Fair Value
    Economic Moat
    17 hours agoArgus Research
View more
  • PR Newswire

    Virax Biolabs Appoints Richard Pallin as the Vice President of In Vitro Diagnostic Sales

    Virax Biolabs ("Virax" or the "Company") (Nasdaq: VRAX), an innovative biotechnology company focused on the prevention, detection, and diagnosis of viral diseases, announced today the appointment of Richard Pallin as Vice President of In Vitro Diagnostic Sales.

  • PR Newswire

    Virax Biolabs Group Limited Announces Closing of $3.8 Million Private Placement

    Virax Biolabs Group Limited ("Virax" or the "Company") (Nasdaq: VRAX), an innovative biotechnology company focused on the prevention, detection, and diagnosis of viral diseases, announced today the closing of its previously announced private placement of 2,330,000 ordinary shares (or ordinary shares equivalents in lieu thereof) at a gross purchase price of $1.65 per share. Additionally, as part of the transaction, Virax has issued unregistered warrants to purchase up to 3,495,000 ordinary shares

  • PR Newswire

    Virax Biolabs Group Limited Announces $3.8 Million Private Placement

    Virax Biolabs Group Limited ("Virax" or the "Company") (Nasdaq: VRAX), an innovative biotechnology company focused on the prevention, detection, and diagnosis of viral diseases, announced today that it has entered into a definitive agreement with a leading healthcare-focused institutional investor, pursuant to which the Company agreed to sell 2,330,000 shares of ordinary shares (or ordinary shares equivalents in lieu thereof) at a gross purchase price of $1.65 per share. Additionally, Virax has

Advertisement
Advertisement